Shenzhen Weiguang Biological Products Co., Ltd. (SHE:002880)

China flag China · Delayed Price · Currency is CNY
25.74
+0.06 (0.23%)
Apr 29, 2026, 3:04 PM CST
-6.98%
Market Cap 5.84B
Revenue (ttm) 1.26B
Net Income (ttm) 233.54M
Shares Out 226.80M
EPS (ttm) 1.03
PE Ratio 25.00
Forward PE n/a
Dividend 0.20 (0.78%)
Ex-Dividend Date Jul 17, 2025
Volume 1,044,379
Average Volume 1,740,553
Open 26.02
Previous Close 25.68
Day's Range 25.54 - 26.02
52-Week Range 25.03 - 33.79
Beta 0.40
RSI 34.83
Earnings Date Apr 27, 2026

About SHE:002880

Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 198... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1985
Employees 859
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002880
Full Company Profile

Financial Performance

In 2025, SHE:002880's revenue was 1.27 billion, an increase of 5.28% compared to the previous year's 1.20 billion. Earnings were 246.32 million, a decrease of -2.84%.

Financial Statements

News

There is no news available yet.